natgillin/translations-raw huggingface dataset:
Patients who cannot swallow tablets should use an oral solution of lamivudine, or alternatively they may crush the tablets and add them to a small amount of food or drink immediately before swallowing it.
Bolniki, ki ne morejo pogoltniti celih tablet, naj uporabijo peroralno raztopino lamivudina ali pa naj tablete zdrobijo in jih tik pred zaužitjem zmešajo z majhno količino hrane ali pijače.
The full EPAR for Lamivudine Teva Pharma B.V. can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Lamivudine Teva Pharma B.V je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For more information about treatment with Lamivudine Teva Pharma B.V., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Lamivudine Teva Pharma B.V preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Lamivudine Teva Pharma B.V. is used in combination with other antiviral medicines to treat adults and children infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Lamivudine Teva Pharma B.V se uporablja v kombinaciji z drugimi protivirusnimi zdravili za zdravljenje odraslih in otrok, ki so okuženi z virusom humane imunske pomanjkljivosti (HIV), to je virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
This means that Lamivudine Teva Pharma B.V. is similar to a ‘reference medicine' already authorised in the European Union (EU) called Epivir.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Epivir.
The recommended dose of Lamivudine Teva Pharma B.V. for adults and children weighing at least 25 kg is 300 mg a day.
za odrasle in otroke, ki tehtajo vsaj 25 kg, je 300 mg na dan.
Therefore, the CHMP's view was that, as for Epivir, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Epivir odtehtajo znana tveganja.
The European Commission granted a marketing authorisation valid throughout the EU for Lamivudine Teva Pharma B.V. on 10 December 2009.
Evropska komisija je dovoljenje za promet z zdravilom Lamivudine Teva Pharma B.V , veljavno po vsej Evropski uniji, izdala 10. decembra 2009.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lamivudine Teva Pharma B.V.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
This is a summary of the European public assessment report (EPAR) for Lamivudine Teva Pharma B.V.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Lamivudine Teva Pharma B.V.
An oral solution of lamivudine can be used to achieve the appropriate dose.
Ustrezen odmerek se lahko doseže z uporabo peroralne raztopine lamivudina.
What measures are being taken to ensure the safe and effective use of Lamivudine Teva Pharma B.V.?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Lamivudine Teva Pharma B.V.
Because Lamivudine Teva Pharma B.V. is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Lamivudine Teva Pharma B.V. does not cure HIV infection or AIDS, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS.
ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
The active substance in Lamivudine Teva Pharma B.V., lamivudine, is a nucleoside reverse transcriptase inhibitor (NRTI).
Zdravilna učinkovina v zdravilu Lamivudine Teva Pharma B.V., lamivudin, je zaviralec nukleozidne reverzne transkriptaze (NRTI).
What are the benefits and risks of Lamivudine Teva Pharma B.V.?
Kakšne so koristi in tveganja, povezani z zdravilom Lamivudine Teva Pharma B.V.
Lamivudine Teva Pharma B.V., taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
v kombinaciji z drugimi protivirusnimi zdravili zmanjša količino virusa HIV v krvi in ga ohranja na nizki ravni.
Because Lamivudine Teva Pharma B.V. is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Epivir.
generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Epivir.
Other information about Lamivudine Teva Pharma B.V.
Druge informacije o zdravilu Lamivudine Teva Pharma B.V.
The CHMP concluded that, in accordance with EU requirements, Lamivudine Teva Pharma B.V. has been shown to have comparable quality and to be bioequivalent to Epivir.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Lamivudine Teva Pharma B.V.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lamivudine Teva Pharma B.V. have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Lamivudine Teva Pharma B.V.
What is Lamivudine Teva Pharma B.V.?
Kaj je zdravilo Lamivudine Teva Pharma B.V.
The Committee recommended that Lamivudine Teva Pharma B.V. be given marketing authorisation.
Priporočil je, da se za zdravilo Lamivudine Teva Pharma B.V.
Lamivudine Teva Pharma B.V. is an antiviral medicine containing the active substance lamivudine.
je protivirusno zdravilo, ki vsebuje zdravilno učinkovino lamivudin.
Why has Lamivudine Teva Pharma B.V. been approved?
Zakaj je bilo zdravilo Lamivudine Teva Pharma B.V.
Date of latest renewal: 19 july 2017
Datum zadnjega podaljšanja: 19 julij 2017
- If you are pregnant or believe you may be pregnant.
− Če ste noseči ali menite, da bi lahko bili noseči.
Time points for measurements were 2 minutes, 30 minutes, 1 hour, 4 hours, 6 hours, 12 hours, 24 hours, 2 days, 4 days, 6 days.
Časovne točke meritev so bile 2 minuti, 30 minut, 1 ura, 4 ure, 6 ur, 12 ur, 24 ur, 2 dni, 4 dni, 6 dni.
Special precautions for relatives, carers and hospital staff are provided in section 6.6.
Posebni previdnostni ukrepi za sorodnike, negovalce in bolnišnično osebje so navedeni v poglavju 6.6.
adult female (60 kg)
odrasla ženska (60 kg)
You will not have to store this medicinal product.
Tega zdravila vam ne bo treba shranjevati.
In any case the blood parameters of the patient have to be monitored and the appropriate actions immediately taken if there is evidence of damages.
V vsakem primeru je treba opazovati bolnikove krvne parametre in takoj ustrezno ukrepati, če se pokažejo znaki okvar.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 23 august 2012
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 23 avgust 2012
rates and the accumulated dose depend on many factors.
Površinski odmerki in akumuliran odmerek so odvisni od mnogo dejavnikov.
Any woman who has missed a period should be assumed to be pregnant until proven otherwise.
Pri vsaki ženski, ki ni dobila menstruacije, je treba predpostavljati, da je noseča, dokler ni dokazano nasprotno.
The use of television monitor systems to monitor the patients is recommended.
Prav tako se za spremljanje bolnikov priporoča uporaba sistema televizijskih zaslonov.
The volume varies from 1 to 3 mL.
Prostornina se spreminja od 1 do 3 ml.
These complexes are rapidly eliminated by the kidneys.
Ti kompleksi se hitro izločijo prek ledvic.
Copper-64 has a half-life of 12.7 hours.
Baker-64 ima razpolovni čas 12,7 ure.
Activity measurements using an ionisation chamber are very sensitive to geometric factors and, therefore, should be performed only under geometric conditions which have been appropriately validated.
Meritve aktivnosti z uporabo ionizacijske celice so zelo občutljive za geometrične faktorje in jih je zaradi tega treba izvajati samo pod geometričnimi pogoji, ki so bili primerno potrjeni.
ANNEX IV GROUNDS FOR ONE ADDITIONAL RENEWAL
PRILOGA IV RAZLOGI ZA DODATNO PODALJŠANJE
Toxicity of copper compounds has been extensively investigated both in human and in animals.
Toksičnost bakrovih spojin je bila obširno raziskana na ljudeh in tudi na živalih.
These medicines act as a carrier to take the radioactivity to where it is needed.
Ta zdravila delujejo kot prenašalci, ki prenesejo radioaktivnost tja, kjer je potrebna.
Dispose in accordance with local requirements.
Odstranjevanje v skladu z lokalnimi predpisi.
In all cases, it is necessary to ensure that the risks of the radiation are less than from the disease itself.
V vsakem primeru je treba zagotoviti, da so tveganja zaradi sevanja manjša od same bolezni.
Blood radioactivity decreased from 60.3 % to 3.4 % after 1 hour, and then it decreased of 1 % after 6 hours, and increased to 5.6 % and 4.9 % after 12-24 hours.
Radioaktivnost krvi se je po 1 uri zmanjšala s 60,3 % na 3,4 % ter po 6 urah še za 1 %, nato je po 1224 urah narasla na 5,6 % in 4,9 %.
Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.
Njihovo sprejemanje, shranjevanje, uporabo, prenos in odstranjevanje urejajo predpisi in/ali ustrezna dovoljenja pristojnih organov.
Then copper re-emerges in plasma and is distributed to other organs.
Baker se ponovno pojavi v plazmi in se porazdeli v druge organe.
Disappearance of radioactivity
Pojemanje radioaktivnosti
The chelating efficacy is greatest immediately or within one hour of exposure when the radionuclide is circulating in or available to tissue fluids and plasma.
Učinkovitost keliranja je največja takoj ali eno uro po izpostavljenosti, ko radionuklid kroži ali je v tkivni tekočini in plazmi.
Usual precautions regarding sterility and radioactivity must be respected.
Treba je upoštevati običajne varnostne ukrepe glede sterilnosti in radioaktivnosti.
The very limited exposure to Cuprymina (cumulative total sales of 152 vials in the EU) is considered to constitute grounds for requiring an additional five-year renewal.
Zelo majhna izpostavljenost zdravilu Cuprymina (kumulativna vsota prodaje v EU je 152 vial), je razlog za zahtevo za dodatno petletno podaljšanje.
MARKETING AUTHORISATION NUMBER EU/1/12/784/001
ŠTEVILKA DOVOLJENJA ZA PROMET Z ZDRAVILOM EU/1/12/784/001
- Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6).
− Ugotovljena nosečnost ali sum nanjo ali kadar nosečnost ni bila izključena (glejte poglavje 4.6).
For instruction on preparation of the medicinal product, see section 12.
Za navodila glede priprave zdravila glejte poglavje 12.
The dosimetry estimates were based on a mouse distribution study and the calculations were effected using OLINDA (Organ Level INternal Dose Assessment Code) (see Table 2).
Dozimetrične ocene temeljijo na študiji porazdelitve pri miših, izračuni pa so bili izvedeni z ocenjevalnim kodeksom OLINDA (Organ Level INternal Dose Assessment Code) (glejte preglednico 2).
If at any time in the preparation of this medicinal product the integrity of this container is compromised it should not be used.
Če je neoporečnost vsebnika kadar koli med pripravo zdravila ogrožena, se ne sme uporabiti.
Pharmacotherapeutic group: various diagnostic radiopharmaceuticals, ATC code: Not yet assigned
Farmakoterapevtska skupina: Razni radiodiagnostiki, oznaka ATC: še ni bila dodeljena
These persons will take special care for the safe use of this medicinal product and will keep you informed of their actions.
Ti bodo zlasti pozorni na varno uporabo zdravila in vas bodo sproti obveščali o svojem ravnanju.
The vial should never be opened and must be kept inside its shielded container.
Viala se ne sme nikoli odpreti, ostati mora znotraj zaščite.
There are strict laws on the use, handling and disposal of radiopharmaceutical products.
Cuprymina Obstajajo strogi zakoni za uporabo, ravnanje in odstranjevanje radiofarmakov.
These may be substances that have been designed to recognise a particular type of cell in the body, including tumour cells.
Lahko so to učinkovine, ki so bile razvite zato, da v telesu prepoznajo določene vrste celice, med njimi tudi rakave.
With these assumptions the estimated dose for a person in close contact with the patient is 0.46 mSv, which is less than one half of the limit of not exposed people (1 mSv/year).
S temi predpostavkami je ocenjeni odmerek za osebo v tesnem stiku z bolnikom 0,46 mSv, kar je manj kot polovica dovoljene količine za ljudi, ki sevanju niso bili izpostavljeni (1 mSv/leto).
For minimising radiation exposure with repeated exposition there is no recommendation except the strict observance of the above ones.
Za zmanjšanje izpostavljenosti sevanju pri večkratni izpostavljenosti ni drugih priporočil kot strogo upoštevanje navedenega.
This medicinal product will only be handled and given to you by people who are trained and qualified to use it safely.
Z zdravilom bodo ravnali in vam ga dajali le strokovnjaki, usposobljeni za njegovo varno uporabo.
PHARMACEUTICAL FORM AND CONTENTS Volume: {Z} mL
FARMACEVTSKA OBLIKA IN VSEBINA Prostornina: {Z} ml
The following information is intended for the specialist only.
Naslednje informacije so namenjene samo zdravstvenemu osebju.
Table 2: Absorbed dose per unit activity administered
Preglednica 2: Absorbiran odmerek na enoto dane aktivnosti
Table 1 - Condition of negligible radioactivity in the patients Days after injection (2,770 MBq)
Preglednica 1 - Stanje zanemarljive radioaktivnosti pri bolnikih Dnevi po injiciranju (2 770 MBq)
Based upon the data that have become available since the granting of the initial Marketing authorisation, the CHMP considers that the benefit-risk balance of Cuprymina remains positive, but considers that its safety profile is to be closely monitored for the following reasons:
Na podlagi podatkov, ki so bili zbrani po prvi pridobitvi dovoljenja za promet z zdravilom, Odbor za zdravila za uporabo v humani medicini (CHMP) meni, da razmerje med koristmi in tveganji za zdravilo Cuprymina ostaja pozitivno, vendar ocenjuje, da je varnostni profil zdravila treba skrbno spremljati zaradi naslednjih razlogov:
The condition of negligible radioactivity in the patient is reached, in practice, 4 days after injection.
V praksi je pri bolniku doseženo stanje zanemarljive radioaktivnosti 4 dni po injiciranju.
Maximum liver uptake was 4 hours after injection with 57.7 %.
Največji privzem v jetrih je bil 57,7 % 4 ure po injiciranju.
MARKETING AUTHORISATION NUMBER(S) EU/1/12/784/001
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/12/784/001
Before the use of Copper-64-labelled medicinal products, pregnancy should be excluded using an adequate/validated test.
Pred uporabo z bakrom (64Cu) označenih zdravil je treba nosečnost izključiti z uporabo primernega/validiranega testa.
Given the long half-life of Copper-64 it is specially recommended to avoid internal contamination.
Zaradi dolge razpolovne dobe bakra (64Cu) se je še zlasti treba izogibati notranji kontaminaciji.
The European Medicines Agency has waived the obligation to submit the results of the studies with Cuprymina in all subsets of the paediatric population on grounds of lack of significant therapeutic benefit over existing treatments.
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z radiofarmacevtskim predhodnikom Cuprymina za vse podskupine pediatrične populacije zaradi pomanjkanja pomembnih terapevtskih koristi v okviru obstoječih zdravljenj.
Grounds for one additional renewal
Razlogi za dodatno podaljšanje
It will be the smallest quantity necessary to achieve the appropriate outcome, depending on the co-administered medicine and its intended use.
To bo najmanjša količina, potrebna za doseganje primernega izida, glede na sočasno uporabljano zdravilo in njegovo uporabo.
Dose rate (nSv/h)
Odmerek (nSv/h)
Therefore, based upon the safety profile of Cuprymina, which requires the submission of a yearly PSUR, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.
Na podlagi varnostnega profila zdravila Cuprymina, ki zahteva predložitev letne PSUR, je CHMP sklenil, da mora imetnik dovoljenja za promet predložiti dodatno vlogo za podaljšanje čez 5 let.
Healthcare personnel are advised to limit the time of close contact with patients injected with Copper-64-radiopharmaceuticals.
Priporočljivo je, da zdravstveno osebje omeji čas tesnega stika z bolniki, injiciranimi z bakrovim (64Cu) radiofarmakom.
It is not intended for direct use in patients.
Ni namenjeno za neposredno uporabo pri bolnikih.
However, a post-exposure interval > 1 hour does not preclude the administration and effective action of chelator, even if with reduced efficiency.
Čeprav od izpostavljenosti poteče več kot 1 ura, to ne izključuje dajanja in uspešnega delovanja kelatorja, četudi z zmanjšano učinkovitostjo.
Appropriate aseptic precautions must be taken, in order to maintain the sterility of Cuprymina and to maintain sterility throughout the labelling procedures.
Treba je poskrbeti za primerne aseptične varnostne ukrepe, da se vzdržujeta sterilnost radiofarmacevtskega predhodnika Cuprymina in sterilnost med postopki označevanja.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
− Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1;
Please ask your nuclear medicine doctor when you can resume breast-feeding.
Vprašajte zdravnika nuklearne medicine, kdaj lahko nadaljujete dojenje.
Copper-64-labelled medicinal products should not be used in children and adolescents up to 18 years.
Z bakrom (64Cu) označena zdravila se ne smejo uporabljati pri otrocih in mladostnikih, starih do 18 let.
Administration procedures should be carried out in a way to minimise risk of contamination of the medicinal product and irradiation of the operators.
Administrativne postopke je treba izvajati tako, da se čim bolj zmanjša tveganje za okužbo zdravila in obsevanje operaterjev.
If the administration is considered necessary, a breast-feeding mother should be advised to stop breast-feeding.
Če je uporaba nujna, je treba doječi materi svetovati, naj prekine dojenje.
Radiolabelling of carrier molecules, such as peptides, monoclonal antibodies, or other substrates, with Copper (64Cu) chloride is very sensitive to the presence of trace metal impurities.
Radioaktivno označevanje nosilnih molekul, kot so peptidi, monoklonska protitelesa ali drugi substrati, z bakrovim (64Cu) kloridom je zelo občutljivo za prisotnost sledov kovinskih nečistot.
Please read the package leaflet of that medicine carefully.
Pozorno preberite navodilo za uporabo tega zdravila.
It is important that all glassware, syringe needles etc, used for the preparation of the radiolabelled compound are thoroughly cleaned to ensure freedom from such trace metal impurities.
Pomembno je, da so vsa steklovina, igle za brizge itd., ki se uporabljajo za pripravo radioaktivno označenih zdravil, temeljito očiščeni, da se zagotovi odsotnost sledov kovinskih nečistot.
If in doubt about her potential pregnancy (if the woman has missed a period, if the period is very irregular, etc.), alternative techniques not using ionising radiation (if there are any) should be offered to the patient.
Če obstaja negotovost glede nosečnosti (če ni dobila menstruacije, če je menstruacija zelo neredna itd.), je treba bolnici ponuditi uporabo kakšne druge metode (če so na voljo), ki ne vključujejo uporabe ionizirajočega sevanja.
This waiver does however not extend to any diagnostic or therapeutic uses of the medicinal product when linked to a carrier molecule.
Opustitev se ne nanaša na nobeno od diagnostičnih ali terapevtskih uporab radiofarmacevtskega predhodnika, kadar je vezan na nosilno molekulo.
Considering that each MBq of Copper-64 causes a dose rate of 9 nSv/h (at a distance of 2 meters) and that the maximum injected activity is of 2,770 MBq, the initial dose rate is 24,930 nSv/h.
Ob upoštevanju, da en MBq bakra (64Cu) povzroči odmerek 9 nSv/h (na razdalji 2 metra) in da je maksimalna injicirana aktivnost 2.770 MBq, je začetni odmerek 24.930 nSv/h.
Cuprymina is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates.
Radionukleotidni predhodnik Cuprymina se ne sme dajati neposredno bolniku, temveč ga je treba uporabiti za radioaktivno označevanje nosilnih molekul, kot so monoklonska protitelesa, peptidi ali drugi substrati.
SPECIAL STORAGE CONDITIONS Store in the original package that provides protection from radiation, according to local regulation.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v originalni ovojnini, ki ščiti pred sevanjem, v skladu z lokalnimi predpisi.
Each pack contains 1 vial in a tungsten or lead container.
Vsako pakiranje vsebuje 1 vialo v volframovem ali svinčevem vsebniku.
The possible use of chelating therapies could interfere with the use of Copper-64-labelled medicinal products.
Morebitna uporaba kelatnih terapij lahko ovira uporabo z bakrom (64Cu) označenih zdravil.
According to literature reports, it may be considered that both spermatogenetic and genetic damage in male test is are unlikely at the dose of 1,000 MBq.
Glede na poročila iz strokovne literature se lahko sklepa, da je pri odmerku 1.000 MBq le majhna verjetnost za spermatogenetske in genetske okvare v moških testisih.
The duration of stopping will depend on the particular radiolabelled medicinal product.
Trajanje prekinitve bo odvisno od posameznega radioaktivno označenega zdravila.
Therefore, in case of an inadvertent administration of Cuprymina, the radiotoxicity for the patient must be reduced by immediate (i. e. within 1 hour) intravenous administration of preparations containing chelators like Ca-DTPA or Ca-EDTA in order to increase the elimination of the radionuclide from the body.
Zato je treba ob nenamernem vnosu radiofarmacevtskega predhodnika Cuprymina radiotoksičnost pri bolniku zmanjšati s takojšnjo (tj. v roku 1 ure) intravensko uporabo pripravkov, ki vsebujejo kelatorje, kot sta Ca-DTPA ali Ca-EDTA, da bi tako pospešili odstranjevanje radionuklidov iz telesa.
Before administering radiopharmaceuticals to a mother who is breast-feeding, consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breast-feeding, and to the choice of the most appropriate radiopharmaceuticals, bearing in mind the secretion of activity in breast milk.
Pred uporabo radiofarmaka na ženski, ki doji, je treba razmisliti o možni prestavitvi dajanja radionuklida, dokler mati ne neha dojiti, in izbrati najustreznejši radiofarmak, ob upoštevanju njegovega izločanja v materino mleko.
Appropriate aseptic precautions should be taken.
Treba je upoštevati ustrezne varstvene ukrepe za zagotavljanje aseptičnih pogojev.
However, in the case of an overdose, you will receive the appropriate treatment.
Če se to vseeno zgodi, vam bo zdravnik uvedel primerno zdravljenje.
Following intravenous administration, at the beginning most organs contained an amount of radioactivity which represented their content of Copper-64-laden blood.
Po intravenskem dajanju je na začetku večina organov vsebovala količino radioaktivnosti, enako njihovi vsebnosti bakra (64Cu) v krvi.
Before use, packaging and radioactivity must be checked.
NAVODILA ZA PRIPRAVO RADIOFARMAKOV Pred uporabo je treba preveriti pakiranje in radioaktivnost.